Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: Committee Papers

Table of Contents:

• 01 Consultee comments on the ACD - Roche
• 02 Consultee comments on the ACD - Chronic Lymphocytic Leukaemia Support Association
• 03 Consultee comments on the ACD - Royal College of Physicians
• 04 Consultee comments on the ACD - NHS England
• 05 Commentator comments on the ACD - Napp Pharmaceuticals
• 06 Public comments on the ACD received via the NICE website
• 07 Roche Products PAS submission- new evidence
• 08 Roche Products Appendix- new evidence
• 09 ERG critique of Patient Access Scheme submission- new evidence
• 10 ERG critique of Roche Products Appendix- new evidence
• 11 Roche Products PAS Incremental Analyses
• 12 ERG critique of Roche Products PAS Incremental Analyses

Please follow the link at the bottom of this page to download Adobe Reader if required.